LifeSciences BC > News > Industry News > 2014 > Biotechnology Focus – Aquinox Pharmaceuticals prices initial public offering

B.C. Industry News

Biotechnology Focus – Aquinox Pharmaceuticals prices initial public offering

March 11, 2014

Aquinox Pharmaceuticals, Inc. has announced the pricing of its initial public offering of 4,200,000 shares.

The common stock will be offered at a price of $11 per share for an aggregate offering of $46.2 million, before underwriting discounts, commissions and estimated expenses.

Additionally, the Company’s common stock has been approved for listing on the NASDAQ Global Market and will trade under the ticker symbol “AQXP.”

Aquinox has granted the underwriters a 30-day option to purchase up to 630,000 additional shares of common stock at the offering price. Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers and Canaccord Genuity Inc. is acting as co-manager for the offering.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on March 6, 2014. The offering is being made only by means of a prospectus, copies of which may be obtained by contacting Jefferies LLC.